JAK2 and graft versus host disease: Ruxolitinib, a JAK1 and JAK2 inhibitor, is widely used for the treatment of myeloproliferative neoplasms, but has been successfully used to also treat immune-mediated diseases, such as graft vs. host disease (GvHD) (15, 16) and HLH (17), based on its rapid, potent, and pleiotropic influence on the host immune system.